Visiomed Group Share Price London S.E.
Equities
0D13
FR0013481835
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.417 EUR | -0.48% | -.--% | -.--% |
03-26 | Visiomed: share price rises on 'record' 2023 results | CF |
02-13 | Visiomed: 38% increase in annual sales | CF |
Sales 2021 | 7.18M 7.8M 616M | Sales 2022 | 14.44M 15.69M 1.24B | Capitalization | 98.55M 107M 8.46B |
---|---|---|---|---|---|
Net income 2021 | -4M -4.35M -343M | Net income 2022 | -5M -5.43M -429M | EV / Sales 2021 | 1.38 x |
Net cash position 2021 | 1.62M 1.75M 139M | Net Debt 2022 | 3.26M 3.54M 279M | EV / Sales 2022 | 7.05 x |
P/E ratio 2021 |
-1.33
x | P/E ratio 2022 |
-22.7
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98.94% |
1 day | -0.48% |
Managers | Title | Age | Since |
---|---|---|---|
Clement Pacaud
CEO | Chief Executive Officer | 34 | 01-21 |
Investor Relations Contact | - | - | |
Thomas Picquette
SEC | Corporate Secretary | - | 31/03/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | - | - | |
Thomas Picquette
SEC | Corporate Secretary | - | 31/03/22 |
Anne Gaignard
BRD | Director/Board Member | - | 31/03/22 |
1st Jan change | Capi. | |
---|---|---|
-5.16% | 181B | |
+1.94% | 112B | |
-3.42% | 67.92B | |
+4.46% | 50.1B | |
+8.75% | 44.27B | |
+9.39% | 40.41B | |
+23.91% | 31.95B | |
-0.95% | 25.82B | |
+17.27% | 25.29B |
- Stock Market
- Equities
- ALVMG Stock
- 0D13 Stock